Drug profile · INN
tirzepatide
MOUNJARO
tirzepatide (MOUNJARO) is a glucagon-like peptide 1 receptor agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — tirzepatide
- US status
- approved
- Class
- Alimentary tract and metabolism (A10)
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 22
- Data quality
- 0.84
Quick answer
tirzepatide (MOUNJARO) is a glucagon-like peptide 1 receptor agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Glucagon-like peptide 1 receptor agonist
Primary target: Gastric inhibitory polypeptide receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| PMDA | approved | — |
Recent coverage
Weight Loss Medications in 2026: GLP-1 Market Shift
Lilly’s early JAK data raises myelofibrosis competition question
Eli Lilly reported early positive data for a next-generation JAK inhibitor acquired through Ajax. The readout could position Lilly as a potential future competitor to Incyte’s Jakafi in myelofibrosis.
Medicare GLP-1 coverage 2026: Bridge program starts July 1
CMS will launch a temporary Medicare GLP-1 Bridge program on July 1, 2026, creating a new access pathway for eligible beneficiaries. For BD teams, investors, and analysts, the key questions are coverage scope, pricing pressure, and what the demo signals for future reimbursement.
Eli Lilly raises 2026 revenue guidance on Mounjaro demand
Eli Lilly’s latest quarter showed stronger-than-expected Mounjaro demand, prompting a higher 2026 revenue outlook. The update matters for analysts and BD teams tracking obesity-market momentum, trial catalysts, and next earnings milestones.
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is tirzepatide?
tirzepatide (MOUNJARO) is a glucagon-like peptide 1 receptor agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for tirzepatide?
MOUNJARO is a marketed brand name for tirzepatide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tirzepatide?
tirzepatide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.